Sarepta therapeutics to initiate part b of momentum study of srp-5051 in patients with duchenne muscular dystrophy amenable to exon 51 skipping following positive interactions with fda

- company anticipates part b of momentum to serve as pivotal study for srp-5051 and to seek accelerated approval if successful - ambulatory and non-ambulatory patients between the ages of 7 to 21 will be eligible to enroll in part b of momentum

SRPT Ratings Summary

SRPT Quant Ranking